Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Author(s): Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
Issue: May/Jun 2005 - Veterinary Compounding
View All Articles in Issue
Page(s): 242-246
Download in electronic PDF format for $75
Abstract: The purpose of this open-label, nonrandomized, crossover trial was to determine the bioavailability of promethazine formulated in a topical Pluronic lecithin organogel. The study was performed at a tertiary care facility. The study subjects were 15 healthy adult white men aged 21 to 40 years, all of whom met the inclusion criteria. Volunteers with a medical history of promethazine hypersensitivity, epileptic disorder, or extrapyramidal reactions, or who had an abnormal skin condition or were taking any medications were excluded. Promethazine 50 mg in a Pluronic lecithin organogel was applied once to the skin of the nondominant wrist of each of 15 subjects, and the application site was covered with an adhesive bandage. Blood samples were collected at baseline (time zero) before drug administration and at 15, 30, 60, 120, 240, and 360 minutes after drug administration. After a 21-day washout period, 10 of the subjects returned for administration of a single dose of intravenous promethazine 25 mg, and blood samples were again collected at the same time intervals as after the topical dose. A high-performance liquid chromatographic method was used to determine serum concentrations of promethazine. The calculated absolute bioavailability of topical promethazine was 2%. Mean AUC0-8 were 16.63 ng•mL/hour for the topical preparation and 407.15 ng•mL/hour for the intravenous dose. At least 50% of the subjects who received the topical promethazine preparation experienced sedation and 73% experienced drowsiness; however, 100% of those who received intravenous promethazine experienced sedation. Although serum concentrations after application of topical promethazine were much lower than after parenteral administration, the study demonstrated that the topical promethazine formulation was absorbed systemically. These data suggest that further research regarding the bioavailability of promethazine in a topically applied Pluronic lecithin organogel is warranted. Clinical trials are needed that focus on the antiemetic efficacy of this formulation in similar and other populations.
Related Keywords:
promethazine, antiemetic, transdermal preparation, percutaneous drug delivery, emesis, nausea, vomiting, phenothiazine, Pluronic lecithin organogel, PLO, drug carrier, drug vehicle, bioavailability, topical preparation
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
|
May/Jun 2005
Pg. 242-246
|
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
|
Mar/Apr 2004
Pg. 101-105
|
The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Bramwell Bethany L, Williams LaVonn A
|
Jan/Feb 2012
Pg. 62-63
|
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
|
May/Jun 2013
Pg. 247-253
|
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
|
May/Jun 2014
Pg. 256-261
|
Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report
Muller George
|
May/Jun 2009
Pg. 220-221
|
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Allen Loyd V Jr
|
May/Jun 2003
Pg. 180-183
|
BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel)
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 322
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream
Lehman Paul A, Raney Sam G
|
May/Jun 2012
Pg. 248-252
|
Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita
|
Jul/Aug 2014
Pg. 345-347
|
Morphine Sulfate 50 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
May/Jun 2009
Pg. 244
|
Oxycodone Hydrochloride 10 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
May/Jun 2009
Pg. 245
|
Transdermals: The Skin as Part of a Drug Delivery System
Allen Loyd V Jr
|
Jul/Aug 2011
Pg. 308-315
|
The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel
Arnold John J, Asbill Scott
|
Nov/Dec 2009
Pg. 569-571
|
Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model
Bassani August S, Banov Daniel, Lehman Paul A
|
May/Jun 2008
Pg. 270-273
|
Percutaneous Absorption of Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol from ABH Gel
Dahal Amit, Neupane Rabin, Boddu Sai HS, Renukuntla Jwala, Khupse Rahul, Dudley Richard
|
Mar/Apr 2020
Pg. 168-175
|
In Vitro Release Tests of Ketoprofen from Pluronic Lecithin Organogel versus Lipoderm Using Immersion Cells and the Phoenix DB-6 Dry Heat Diffusion Tester
McKinney Rachael D, Dunbar Jacob R
|
May/Jun 2021
Pg. 241-245
|
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita
|
May/Jun 2014
Pg. 253-255
|
Return to Top |